Vilnius-based biotech startup Atrandi Biosciences, which develops advanced droplet microfluidics for high-throughput biological research, has raised $25 million in a Series A funding round led by Lux Capital, with participation from Vsquared Ventures and Practica Capital.
- Founded in 2016 by Linas Mazutis, Atrandi Biosciences develops droplet microfluidic technology for studying individual cells. Their key innovation, the Semi-Permeable Capsule (SPC), isolates single cells and enables high-throughput experiments while keeping each cell separate.
- Atrandi’s advanced tools simplify single-cell analysis and support high-throughput research, including:
- Flux Microfluidic Device: An intuitive platform for high-throughput single-cell isolation.
- Onyx Droplet Generator: A versatile device for single-cell and single-molecule applications.
- Styx High-Throughput Screening Platform: A system for efficient fluorescence-activated droplet sorting.
- With a team of over 65 professionals, Atrandi powers more than 200 research labs worldwide, driving breakthroughs in eukaryotic and microbial genomics.
Details of the deal
- The Series A round was led by Lux Capital, an American venture capital firm that manages over $ 5 billion in assets, investing in innovative science and technology.
“Biological research is entering a new era, and Atrandi is uniquely positioned to equip scientists with the tools to tackle the most complex biological challenges. By advancing SPC-based workflows, Atrandi is empowering researchers to unlock new biological insights that will reshape our understanding of life and disease," explains David Yang, Partner at Lux Capital.
- Vsquared Ventures, a Munich-based VC, has closed its second fund of €214 million to invest in early-stage deep tech startups across Europe. Lithuanian-based VC Practica Capital, Metaplanet, and GRIDS Capital also joined the round.
- The $25 million Series A funding will help Atrandi Biosciences expand into the US market, establish a Boston office, and advance its Semi-Permeable Capsule (SPC) technology. The investment will also support the development of new products, broaden the company’s portfolio, and accelerate its global growth.
"This funding enables us to broaden our product portfolio, strengthen our U.S. presence, and better serve our customers. We’re here to deliver on our vision and help realize the full potential of the Century of Biology," claims Juozas Nainys, CEO and co-founder of Atrandi Biosciences.
